{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:15Z","timestamp":1794047415397,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.281631","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T03:15:00Z","timestamp":1663816500000},"page":"273-277","source":"Crossref","is-referenced-by-count":21,"title":["Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation"],"prefix":"10.3324","volume":"108","author":[{"given":"Eduardo","family":"Rodr\u00edguez-Arbol\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas C.","family":"Zarling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"43443","doi-asserted-by":"crossref","unstructured":"Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017; 31(7):1482-1490.","DOI":"10.1038\/leu.2017.113"},{"key":"43444","doi-asserted-by":"crossref","unstructured":"Short NJ, Zhou S, Fu C. Impact of measurable residual disease on survival outcomes in patients with acute myeloid leukemia: a meta-analysis. JAMA Oncol. 2020; 6(12):1890-1899.","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"43445","doi-asserted-by":"crossref","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767.","DOI":"10.1182\/blood.2021013626"},{"key":"43446","doi-asserted-by":"crossref","unstructured":"Hourigan CS, Dillon LW, Gui G. Pre-MEASURE: multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission. J Clin Oncol. 2022; 40(16 Suppl):7006.","DOI":"10.1200\/JCO.2022.40.16_suppl.7006"},{"key":"43447","doi-asserted-by":"crossref","unstructured":"Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003; 95(9):634-635.","DOI":"10.1093\/jnci\/95.9.634"},{"key":"43448","doi-asserted-by":"crossref","unstructured":"Feng Z. Classification versus association models: should the same methods apply?. Scand J Clin Lab Invest Suppl. 2010; 242:53-58.","DOI":"10.3109\/00365513.2010.493387"},{"key":"43449","doi-asserted-by":"crossref","unstructured":"Walter RB, Estey EH. Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: limitations of predictive models. Blood Rev. 2020; 44:100679.","DOI":"10.1016\/j.blre.2020.100679"},{"key":"43450","doi-asserted-by":"crossref","unstructured":"Paras G, Morsink LM, Othus M. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022; 139(11):1694-1706.","DOI":"10.1182\/blood.2021014804"},{"key":"43451","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"43452","doi-asserted-by":"crossref","unstructured":"Orvain C, Wilson JA, Fang M. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoeitic cell transplantation in adult acute myeloid leukemia. Haematologica. 2022.","DOI":"10.3324\/haematol.2022.281585"},{"key":"43453","doi-asserted-by":"crossref","unstructured":"Walter RB, Othus M, Paietta EM. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. 2015; 29(10):2104-2107.","DOI":"10.1038\/leu.2015.76"},{"key":"43454","doi-asserted-by":"crossref","unstructured":"Dhawale T, Steuten LM, Deeg HJ. Uncertainty of physicians and patients in medical decision making. Biol Blood Marrow Transplant. 2017; 23(6):865-869.","DOI":"10.1016\/j.bbmt.2017.03.013"},{"key":"43455","doi-asserted-by":"crossref","unstructured":"Othus M, Wood BL, Stirewalt DL. Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia. 2016; 30(10):2080-2083.","DOI":"10.1038\/leu.2016.120"},{"key":"43456","doi-asserted-by":"crossref","unstructured":"Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplant. 2020; 55(5):843-850.","DOI":"10.1038\/s41409-019-0729-4"},{"key":"43457","doi-asserted-by":"crossref","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018; 378(13):1189-1199.","DOI":"10.1056\/NEJMoa1716863"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281631\/74854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281631\/75192","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10804\/74854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:22Z","timestamp":1794045742000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281631","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}